BioFire wins FDA nod for blood test; LifeLabs to buy CML for $1.2B;

 @FierceMedDev: Acutus hauls in $21M for a-fib imaging. Article | Follow @FierceMedDev

 @DamianFierce: Not to be outdone by J&J, Medtronic is starting an artificial pancreas study of its own. News | Follow @DamianFierce

 @MichaelGFierce: EnteroMedics files with FDA despite obesity-device trial flop. News | Follow @MichaelGFierce

> Canada's LifeLabs Medical Laboratory Services has agreed to buy diagnostics provider CML Healthcare for about $1.2 billion. Article

> BioFire Diagnostics won FDA clearance for its FilmArray Blood Culture Identification panel, a 27-target test for blood pathogens. News

> Valeant ($VRX) is sweetening the terms on its proposed bond sale, looking to lure investors and close its planned $8.7 billion buyout of Bausch + Lomb. Story

> Roche's ($RHHBY) Ventana Medical has partnered with the Translational Genomics Research Institute to find new cancer biomarkers and accelerate diagnostics development. More

> Aethlon Medical ($AEMD) has won the FDA's blessing to study its Hemopurifier device, designed to treat hepatitis C. Item

> Teleflex ($TFX) has inked a new deal with group purchaser HealthTrust to distribute its LMA line of laryngeal masks. Release

Biotech News

 @FierceBiotech: Astellas bites off $490M deal to develop muscle drugs with Cytokinetics. News | Follow @FierceBiotech

 @JohnCFierce: Bayer beefs up cancer drug pipeline with $520M armed antibody deal with Seattle Genetics. Story | Follow @JohnCFierce

 @RyanMFierce: Where were the breakthrough drugs for diabetes at 2013 ADA? Report | Follow @RyanMFierce

> Isis steals diabetes drug spotlight with new approach to slashing blood fat. More

> Glaxo's diabetes drug fails to beat Takeda's Actos in head-to-head study. Report

> Takeda reorganizes top leadership, corporate structure. Item

Pharma News

 @FiercePharma: Eisai pulls seizure drug Fycompa in Germany to protest "appalling" pricing decision. Article | Follow @FiercePharma

 @EricPFierce: Impax CEO Larry Hsu, whose company has been sidetracked by FDA manufacturing issues, is retiring. Story | Follow @EricPFierce

 @CarlyHFierce: GSK CEO Andrew Witty's M&A aim: Sell more, buy less. Story | Follow @CarlyHFierce

> Merck wins Indian injunction against Januvia copycats. Item

> U.S. Supreme Court protects generic drugmakers in 5-4 ruling. News

> Ranbaxy reportedly has FDA issues at Mohali. More

Biotech Research News

 @EmilyMFierce: Lack of gene could predict earlier onset, severity of multiple sclerosis. Article | Follow @EmilyMFierce

> RNA molecule could reduce fat in bloodstream, regulate high cholesterol. More

> New target could be key to preventing epilepsy. Article

> Virus combo kills brain tumor cells in preclinical model. Story

> Penn scientists create human-cell model of pancreatic cancer. Article

> Antioxidant improves motor functions in mice with Parkinson's. Item

Pharma Manufacturing News

> India court quashes lawsuit against Ranbaxy plants. Item

> Pfizer quells fears of cuts at Ireland plant that makes Viagra. More

> Impax to get new CEO as it tries to right manufacturing issues. Article

> U.S. gets EU waiver on APIs in the nick of time. Story

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.